<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29382382</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>08</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1916-0216</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jan</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of otolaryngology - head &amp; neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale</Title>
          <ISOAbbreviation>J Otolaryngol Head Neck Surg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>9</StartPage>
          <MedlinePgn>9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40463-018-0256-0</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Muckle-Wells syndrome (MWS) is a rare auto-inflammatory disease characterized by the presence of recurrent urticaria, deafness and amyloidosis. Progressive sensorineural hearing loss (SNHL) is reported to occur in up to 85% of patients occurring in the second and third decades and as early as the first decade in patients with a more severe phenotype, thus potentially having a significant impact on a child's development. IL-1 inhibitors, such as Anakinra, have been described to improve systemic inflammation, and stabilize or improve hearing status as well. However, complete resolution of hearing loss has been rarely reported. The objective of this article is to highlight the clinical presentation of a pediatric patient with a severe form of MWS and report on the complete resolution of SNHL with the use of Anakinra.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 3-year-old boy was referred to our hospital to assess for the possibility of MWS given a history of hives and recurrent episodes of fever with a family history of MWS in his mother. Of note, the patient's history was significant for conductive hearing loss, speech delay, as well as recurrent acute otitis media episodes. Genetic analysis was performed and diagnosis of MWS was confirmed due to the presence of a NLRP3 gene mutation. Further work-up demonstrated the presence of papilledema and elevation of systemic inflammatory markers for which Canakinumab was initiated. Despite initiation of this treatment, audiogram evaluation demonstrated a new right-sided SNHL. Lumbar puncture also revealed aseptic meningitis. Canakinumab was eventually discontinued and Anakinra initiated. Within 7 months of treatment with Anakinra at 5 mg/kg sc daily, resolution of the SNHL was observed. With further escalation of the Anakinra dose, there was also complete resolution of the aseptic meningitis.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Progressive hearing loss is a significant finding in patients with MWS. Early screening as well as initiation of Anakinra can lead to complete resolution of SNHL even in a patient with a severe spectrum of MWS. However, as this case demonstrates, longer treatment duration and higher doses of Anakinra may be required to achieve this.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Marchica</LastName>
            <ForeName>Cinzia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Otolaryngology Head and Neck Surgery, McGill University Health Center, Montreal Children's Hospital, 1001, boul. Décarie - Local A02.3017, Montreal, QC, H4A 3J1, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zawawi</LastName>
            <ForeName>Faisal</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Otolaryngology Head and Neck Surgery, McGill University Health Center, Montreal Children's Hospital, 1001, boul. Décarie - Local A02.3017, Montreal, QC, H4A 3J1, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basodan</LastName>
            <ForeName>Dania</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Rheumatology, McGill University Health Center, Montreal Children's Hospital, 1001 Decarie, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scuccimarri</LastName>
            <ForeName>Rosie</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Rheumatology, McGill University Health Center, Montreal Children's Hospital, 1001 Decarie, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daniel</LastName>
            <ForeName>Sam J</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Otolaryngology Head and Neck Surgery, McGill University Health Center, Montreal Children's Hospital, 1001, boul. Décarie - Local A02.3017, Montreal, QC, H4A 3J1, Canada. sam.daniel@mcgill.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Otolaryngol Head Neck Surg</MedlineTA>
        <NlmUniqueID>101479544</NlmUniqueID>
        <ISSNLinking>1916-0208</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C507763">IL1RN protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056587" MajorTopicYN="N">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006319" MajorTopicYN="N">Hearing Loss, Sensorineural</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anakinra</Keyword>
        <Keyword MajorTopicYN="N">Hearing loss</Keyword>
        <Keyword MajorTopicYN="N">Muckle-wells syndrome</Keyword>
      </KeywordList>
      <CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This case report was conducted in the tertiary healthcare center of the Montreal Children’s Hospital of the McGill University Health Centre (MUHC). Ethical approval by the research ethics boards (REB) of the MUHC was obtained. CONSENT FOR PUBLICATION: Consent for publication was obtained by the patient and his legal guardians (patient’s parents in this case). COMPETING INTERESTS: RS has received honoraria from Sobi Canada and Novartis Pharmaceuticals Canada. The other authors have no competing interests to declare. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29382382</ArticleId>
        <ArticleId IdType="pmc">PMC5791344</ArticleId>
        <ArticleId IdType="doi">10.1186/s40463-018-0256-0</ArticleId>
        <ArticleId IdType="pii">10.1186/s40463-018-0256-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-wells syndrome and response to anakinra. Arthritis Rheum. 2004;50(2):607–612. doi: 10.1002/art.20033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.20033</ArticleId>
            <ArticleId IdType="pubmed">14872505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muckle TJ. The 'Muckle-Wells' syndrome. Br J Dermatol. 1979;100(1):87–92. doi: 10.1111/j.1365-2133.1979.tb03572.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2133.1979.tb03572.x</ArticleId>
            <ArticleId IdType="pubmed">427013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Koitschev A, Tyrrell PN, Plontke SK, Deschner N, Hansmann S, et al.  Early detection of sensorineural hearing loss in Muckle-wells-syndrome. Pediatr Rheumatol Online J. 2015;13(1):43. doi: 10.1186/s12969-015-0041-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12969-015-0041-9</ArticleId>
            <ArticleId IdType="pmc">PMC4632838</ArticleId>
            <ArticleId IdType="pubmed">26531310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kullenberg T, Lofqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford) 2016;55(8):1499–1506. doi: 10.1093/rheumatology/kew208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kew208</ArticleId>
            <ArticleId IdType="pmc">PMC4957676</ArticleId>
            <ArticleId IdType="pubmed">27143789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011;13(2):123–131. doi: 10.1007/s11926-011-0165-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-011-0165-y</ArticleId>
            <ArticleId IdType="pmc">PMC3195512</ArticleId>
            <ArticleId IdType="pubmed">21538043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581–592. doi: 10.1056/NEJMoa055137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa055137</ArticleId>
            <ArticleId IdType="pmc">PMC4178954</ArticleId>
            <ArticleId IdType="pubmed">16899778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmadi N, Brewer CC, Zalewski C, King KA, Butman JA, Plass N, et al.  Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol Head Neck Surg. 2011;145(2):295–302. doi: 10.1177/0194599811402296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0194599811402296</ArticleId>
            <ArticleId IdType="pmc">PMC3407887</ArticleId>
            <ArticleId IdType="pubmed">21493283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kone-Paut I, Galeotti C. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2015;11(10):1083–1092. doi: 10.1586/1744666X.2015.1077702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/1744666X.2015.1077702</ArticleId>
            <ArticleId IdType="pubmed">26312542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummenhofer K, et al.  Treatment of Muckle-wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15(3):R64. doi: 10.1186/ar4237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4237</ArticleId>
            <ArticleId IdType="pmc">PMC4060562</ArticleId>
            <ArticleId IdType="pubmed">23718630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Headley AP, Cordingley F, Hawkins PN, Riminton DS. Muckle-wells cryopyrinopathy: complex phenotyping and response to therapy in a new multiplex kindred. Inflammation. 2014;37(2):396–401. doi: 10.1007/s10753-013-9752-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-013-9752-6</ArticleId>
            <ArticleId IdType="pubmed">24150829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, et al.  NLRP3 E311K mutation in a large family with Muckle-wells syndrome--description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011;13(6):R196. doi: 10.1186/ar3526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar3526</ArticleId>
            <ArticleId IdType="pmc">PMC3334646</ArticleId>
            <ArticleId IdType="pubmed">22146561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, Hansmann S, Plontke SK, Koitschev C, et al.  Hearing loss in Muckle-wells syndrome. Arthritis Rheum. 2013;65(3):824–831. doi: 10.1002/art.37810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.37810</ArticleId>
            <ArticleId IdType="pubmed">23440695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalgic B, Egritas O, Sari S, Cuisset L. A variant Muckle-wells syndrome with a novel mutation in CIAS1 gene responding to anakinra. Pediatr Nephrol. 2007;22(9):1391–1394. doi: 10.1007/s00467-007-0500-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00467-007-0500-8</ArticleId>
            <ArticleId IdType="pubmed">17486372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, et al.  Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-wells syndrome. Arthritis Rheum. 2011;63(3):840–849. doi: 10.1002/art.30149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.30149</ArticleId>
            <ArticleId IdType="pubmed">21360513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 2005;52(4):1283–1286. doi: 10.1002/art.20953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.20953</ArticleId>
            <ArticleId IdType="pubmed">15818707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirault T, Launay D, Cuisset L, Hachulla E, Lambert M, Queyrel V, et al.  Recovery from deafness in a patient with Muckle-wells syndrome treated with anakinra. Arthritis Rheum. 2006;54(5):1697–1700. doi: 10.1002/art.21807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.21807</ArticleId>
            <ArticleId IdType="pubmed">16646042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al.  Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258–267. doi: 10.1002/art.25057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.25057</ArticleId>
            <ArticleId IdType="pubmed">20039428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64(7):2375–2386. doi: 10.1002/art.34409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34409</ArticleId>
            <ArticleId IdType="pmc">PMC3474541</ArticleId>
            <ArticleId IdType="pubmed">22294344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamazaki T, Masumoto J, Agematsu K, Sawai N, Kobayashi S, Shigemura T, et al.  Anakinra improves sensory deafness in a Japanese patient with Muckle-wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum. 2008;58(3):864–868. doi: 10.1002/art.23261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.23261</ArticleId>
            <ArticleId IdType="pubmed">18311804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. Hearing improvement in a patient with variant Muckle-wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis. 2006;65(4):533–534. doi: 10.1136/ard.2005.038091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2005.038091</ArticleId>
            <ArticleId IdType="pmc">PMC1798106</ArticleId>
            <ArticleId IdType="pubmed">16531551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koitschev A, Gramlich K, Hansmann S, Benseler S, Plontke SK, Koitschev C, et al.  Progressive familial hearing loss in Muckle-wells syndrome. Acta Otolaryngol. 2012;132(7):756–762. doi: 10.3109/00016489.2012.656321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00016489.2012.656321</ArticleId>
            <ArticleId IdType="pubmed">22497426</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
